drugset / Trial / NCT01438827

Avanz Phleum Pratense Maintenance Dose

NCT01438827 ↗

Phase 2/3 Completed 450 enrolled ALK-Abelló A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the trial is to evaluate the efficacy of two dosing schedules of Avanz SQ+ (Standardised Quality) Phleum pratense compared to placebo in subjects with grass pollen induced allergic rhinoconjunctivitis with or without asthma.

Timeline

Start
2011-09
Primary completion
2012-12
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator AVANZ Phleum pratense Unknown 4000 unknown Other
Comparator AVANZ Phleum pratense Unknown 15000 unknown Other

Indications